Wednesday, January 19, 2022 9:25:38 AM
Every time someone talks about a buy-out I think about this sort of thing. Yeah, the big pharmaceutical companies have money and expertise. They can push through to approval. They have the management expertise to run the company after approval. But they are NOT in the business of personalized therapies. They are in the business of shots and pills. Mass produce, mass market, sell as much as you can regardless of need, efficacy, or side effects.
You need look no farther than the Oxy market to see how this all plays out. If BP bought NWBO earlier what would be their incentive to get it across the finish line and create a new Standard of Care? They can make far more money far more easily with patients getting radiation, chemo and a bunch of useless treatments, and treatments to help mitigate or mask the side-effects of those treatments, than they could by actually curing people.
The longer NWBO holds out and the farther they make it on their own, the more money BP will need to shell out and the harder it will be to bury DC-Vax in the Closet of Actual Effectiveness.
So yeah, maybe we could all be using our $5-$10 per share buyout money right now and wonder why no one ever hears about that dendric cell vaccine that had so much promise. Or, maybe we get to be part of financing an actual cure for cancer and walk away with a much higher amount per share in the coming months.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM